Select Bibliography

Filter by any of these (after searching):

Amrein, Philip C.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J Clin Oncol - 2013

Manuscript - Primary - Primary - Leukemia - CALGB-10502

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Moore, Joseph O. , George, Stephen L. , Dodge, Richard K. ... - - Blood - 2005

Manuscript - Primary - Primary - Leukemia - CALGB-9222